Emergent Biosolutions EBS Accrued Liabilities, Current
Accrued Liabilities, Current at other companies
Other financials
Where this comes from
Reported directly by Emergent Biosolutions in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Emergent Biosolutions's accrued liabilities, current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Emergent Biosolutions's accrued liabilities, current?
- Emergent Biosolutions (EBS) reported accrued liabilities, current of $9.4M in Q1 2026.
- How has Emergent Biosolutions's accrued liabilities, current changed year-over-year?
- Emergent Biosolutions's accrued liabilities, current decreased by 28.8% year-over-year, from $13.2M to $9.4M.
- What is the long-term trend for Emergent Biosolutions's accrued liabilities, current?
- Over 5 years (2020 to 2025), Emergent Biosolutions's accrued liabilities, current has grown at a -23.6% compound annual growth rate (CAGR), from $46.9M to $12.2M.